Phosphodiesterases are a superfamily of hydrolase enzymes whose job is singular but consequential: they terminate cyclic nucleotide signaling by converting cAMP and cGMP into their inactive 5′-AMP and 5′-GMP forms. This matters because cAMP and cGMP, generated by adenylyl and guanylyl cyclases after receptor activation, are second messengers that regulate everything from heart contractility and smooth-muscle tone to immune-cell activation and memory. Without PDEs, the signal would never switch off. In humans, the family is built from roughly 21 genes that produce more than 100 isoforms, organized into 11 families — PDE1 through PDE11 — each defined by sequence, structure, and which cyclic nucleotide it prefers. The sheer number of isoforms is the source of both the field's richness and its difficulty: the same messenger can be cleared with exquisite spatial and temporal control.

Browse More Phosphodiesterases Products

How the eleven families are classified

The cleanest way to organize the 11 families is by what they hydrolyze. PDE4, PDE7, and PDE8 are cAMP-selective. PDE5, PDE6, and PDE9 are cGMP-selective. PDE1, PDE2, PDE3, PDE10, and PDE11 are dual-substrate enzymes that handle both, often with context-dependent preference. Beyond substrate, the families differ in how they are regulated, which is what lets the two messenger systems talk to each other: PDE1 is calcium/calmodulin-stimulated, PDE2 is allosterically activated by cGMP, and PDE3 is inhibited by cGMP. These cross-connections mean that raising one messenger can, through a PDE, lower the other — a design that produces precise signaling microdomains inside the cell.

Figure 1. Common structure of the different PDE enzymes. (Source: Barone I, et al. 2017)

PDE3 — the cardiac and platelet switch

PDE3 is a dual-substrate enzyme with a distinctive property: it is inhibited by cGMP. This makes it a built-in integrator of the two messenger systems, because when cGMP rises, PDE3 is restrained and cAMP climbs in the same cell. PDE3 is also the dominant cAMP-hydrolyzing activity in cardiac myocytes and platelets, so its inhibition simultaneously increases myocardial contractility (by raising cAMP and PKA activity) and blocks platelet aggregation — the dual basis for its use in decompensated heart failure and peripheral arterial disease. Because the enzyme is also present in vascular smooth muscle, its inhibition relaxes tone there as well. The clinical ceiling is set by cAMP elevation in the brainstem emetic centers, which limits tolerability, a recurring theme across the superfamily that explains why isoform selectivity is pursued so aggressively.

PDE4 — the inflammatory and airway workhorse

PDE4 is cAMP-selective and is the major cAMP-hydrolyzing activity in inflammatory cells (neutrophils, macrophages, and T cells) and in airway smooth muscle. It is built from four subfamilies (A–D) and a large set of splice variants, each scaffolded to different signaling complexes, which is why it shapes cytokine production, immune-cell trafficking, and bronchial tone rather than acting as a single switch. Inhibiting PDE4 raises intracellular cAMP, dampening inflammatory signaling and relaxing airway muscle — the principle behind therapies for COPD and chronic inflammatory skin disease. Its vulnerability is again the nausea threshold, because cAMP in the area postrema drives emesis; newer agents are engineered for anti-inflammatory potency at doses that stay below that threshold, and some are delivered topically to avoid systemic cAMP swings.

PDE5 — the cGMP guardian of vascular and pulmonary tone

PDE5 is strictly cGMP-selective and sits in vascular and pulmonary smooth muscle and related erectile tissue. By degrading cGMP, it sets the resting tone of these muscles; inhibiting it protects cGMP and sustains smooth-muscle relaxation. This is the mechanism behind its use in pulmonary arterial hypertension, where it lowers pulmonary vascular resistance, and in erectile dysfunction, where it relaxes corpus-cavernosum smooth muscle. PDE5 acts upstream of PKG-mediated vasodilation, and its selectivity for cGMP over cAMP is exactly what gives the class its vascular rather than cardiac profile. Because cGMP and cAMP are handled by different families, a PDE5 agent leaves cardiac cAMP largely untouched — a clean separation that underpins its safety window.

Together, PDE3, PDE4, and PDE5 account for essentially all clinically approved phosphodiesterase inhibitors, and their differences explain the distinct indications: a cardiac-and-platelet agent, an anti-inflammatory-and-airway agent, and a vascular-and-pulmonary agent. The shared challenge is selectivity — broadly raising cAMP triggers nausea through brainstem emetic centers, which is why modern programs chase isoform- and tissue-restricted molecules rather than blanket inhibition.

PDE2, PDE9, and PDE10 — the rising CNS and oncology targets

Three further families are drawing the most recent research attention. PDE2 is cGMP-stimulated and dual-substrate, enriched in brain and heart, where it acts as a cGMP-to-cAMP cross-talk node; its inhibition is explored for cognition and neuropsychiatric indications because it can amplify cyclic-nucleotide signaling specifically where cGMP is already high. PDE9 is the most cGMP-selective family, concentrated in brain and vascular smooth muscle, and is pursued for cognition and Alzheimer's-related signaling, with the advantage that its strict substrate preference avoids the broad cAMP effects that cause nausea. PDE10 is dual but prefers cAMP and is strikingly enriched in the striatum, making it a candidate target in movement disorders, schizophrenia, and certain tumors. These three illustrate the modern direction of the field: moving from broadly acting agents toward individual isoforms and defined brain circuits, where a single family's distribution predicts both the desired effect and the side-effect profile.

How PDE activity and isoforms are measured

Measuring PDEs starts with the cyclic nucleotide itself. Competitive or direct ELISA kits quantify cAMP and cGMP in cell lysates, supernatants, or plasma and show whether a pathway is active. Enzyme activity is read in vitro by supplying radiolabeled or fluorescent cyclic nucleotide substrate and measuring the hydrolyzed product, often with recombinant isoforms to assign family-specific contributions. Isoform abundance is profiled by quantitative PCR or Western blot, while inhibitor screening uses recombinant PDEs in biochemical or cell-based formats. The right combination — messenger measurement plus isoform-resolved activity — is what connects a genetic or pharmacological perturbation to a physiological readout.

For research and diagnostic teams, the practical tasks are quantifying the messengers and the enzymes that clear them. Our catalog supports this with cyclic-nucleotide ELISA kits (for intracellular and released cAMP/cGMP), phosphodiesterase activity-assay reagent sets, and custom development for isoform-specific detection and small-molecule screening.